about
Nontargeted Effect after Radiotherapy in a Patient with Non-Small Cell Lung Cancer and Bullous PemphigoidA case of recurrent breast cancer with solitary metastasis to the urinary bladder.Palliative Radiotherapy with or without Additional Care by a Multidisciplinary Palliative Care Team: A Retrospective Comparison.Survival prediction score: a simple but age-dependent method predicting prognosis in patients undergoing palliative radiotherapy.Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases?Development of a score predicting survival after palliative reirradiation.Patient-reported symptoms before palliative radiotherapy predict survival differences.Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations.Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneousManagement of patients with metastatic prostate cancer (mPC) in a rural part of North Norway with a scattered population: does living near the department of oncology translate into a different pattern of care and survival?Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastasesProvider decision regret-a useful method for analysis of palliative thoracic re-irradiation for lung cancer?Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA)Feasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care settingIs there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?Long-term survival results after treatment for oligometastatic brain diseaseSecond re-irradiation: A delicate balance between safety and efficacyRisk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer
P50
Q35988058-A86F39EF-FCFD-4C10-A179-5484FCB38732Q37673377-744E91CB-BB9A-4EEF-A899-1BB39B64AAFDQ37731423-632DD580-4F2D-487B-B72E-246EFB7CC46EQ38632096-2A91C312-7402-480F-BFC2-013D55EEA313Q40571923-2CD98B0D-C6DB-449A-B630-17D84E6B3AFAQ42207668-F0D6FFB5-EB1C-4C12-B02C-6EE8C9169BA1Q47854791-91B1F0AC-38B8-4516-A91E-549B0125DB92Q48179834-26B61B60-EB03-4194-96F5-39A2B6AB999DQ64248136-E0F4F414-0AAF-4608-B22B-26BDFDE91F71Q64900607-88A94C7D-7A8C-44DD-A78D-8116D1D1AD6CQ87973022-0135CEFF-6B16-4723-953F-CACE869F8170Q89459019-B9DA6265-D5FB-4954-8250-628F2709706AQ89699656-A8E2844F-7945-4A41-9694-D868835D49A1Q89855122-C4002A0B-4E80-4D5A-8F1C-CBFD6249358FQ90458058-39789370-4D78-4FB8-BB40-CFB6557E0AABQ90478119-2EC79586-580B-481A-BCB1-7C28EB3C5BD2Q91008843-6A55CC20-140C-4A09-A7A7-69DCCD097274Q94481971-A17D4264-28B6-4F02-8348-8DCCF7C07678
P50
description
researcher ORCID ID = 0000-0003-1592-2908
@en
wetenschapper
@nl
name
Carsten Nieder
@ast
Carsten Nieder
@en
Carsten Nieder
@es
Carsten Nieder
@nl
type
label
Carsten Nieder
@ast
Carsten Nieder
@en
Carsten Nieder
@es
Carsten Nieder
@nl
prefLabel
Carsten Nieder
@ast
Carsten Nieder
@en
Carsten Nieder
@es
Carsten Nieder
@nl
P1006
P214
P1006
P106
P214
P31
P496
0000-0003-1592-2908
P7859
lccn-n2002160127